CMC ANALYSIS & QUALITY CONTROL – GMP CERTIFIED AND FDA INSPECTED CRO
Testimonials
![Celltrion logo](https://kymos.com/wp-content/uploads/2021/11/Celltrion-logo-300x76.png)
“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”
![Combino_Logo](https://kymos.com/wp-content/uploads/2021/11/Combino_Logo.png)
“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”
![Helm Logo](https://kymos.com/wp-content/uploads/2021/12/HELM_Logo-200.png)
“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”
![PharmaMar Logo](https://kymos.com/wp-content/uploads/2021/12/PharmaMar_Logo-200.png)
“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”
![Exeltis_Logo](https://kymos.com/wp-content/uploads/2021/11/Exeltis_Logo-1-300x136.png)
“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”
![Omeicos_Logo](https://kymos.com/wp-content/uploads/2021/11/Omeicos_Logo.png)
“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”
![TEchnical university Darmstadt_Logo](https://kymos.com/wp-content/uploads/2021/11/Darmstadt_Logo-300x125.png)
“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”
KOREA PHARM & BIO: Goyang, KR | 23-26 Apr 2024
BIO KOREA 2024: Seoul, KR | 08-10 May 2024
BIO International Convention: San Diego, US | 3-6 Jun 2024
Congrès POLEPHARMA Biotesting: Évreux, FR | 5-6 Jun 2024
AFI Symposium: Rimini, IT | 5-7 Jun 2024
BIOPLUS – INTERPHEX KOREA: Seoul, KR | 10-12 Jul 2024
Farmaforum: Madrid, ES | 25-26 Sep 2024
Biomarkers Europe 2024: Basel, CH | 30 Sep – 01 Oct 2024
CPHI 2024: Milan, IT | 8-10 Oct 2024
BIO-Europe Autumn: Stockholm, SE | 4-6 Nov 2024
European Bioanalysis Forum: Barcelona, ES | 20-22 Nov 2024
PharmaLab Congress: Düsseldorf, DE | 25-27 Nov 2024
I4ID 2024: Lyon, FR | 27-28 Nov 2024